Evidence map›Paper›PMID 25938476›Full record

ArticlePloS one2015

Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance.

Sandy S Roh, Laura E Smith, Jong Seok Lee, Laura E Via, Clifton E Barry, David Alland, Soumitesh Chakravorty

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Cryptic Microheteroresistance Explains Mycobacterium tuberculosis Phenotypic Resistance.American journal of respiratory and critical care medicine · 2017
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Sandy S RohDepartment of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Laura E SmithDepartment of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Jong Seok LeeDepartment of Microbiology, International Tuberculosis Research Center, Changwon, Gyeongsang, Republic of Korea.
Laura E ViaTuberculosis Research Section, LCID, NIAID, NIH, Bethesda, MD, United States of America.
Clifton E BarryTuberculosis Research Section, LCID, NIAID, NIH, Bethesda, MD, United States of America.
David AllandDepartment of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Soumitesh ChakravortyDepartment of Medicine, New Jersey Medical School, Rutgers University, Newark, New Jersey, United States of America.
Rutgers, The State University of New Jersey · USNational Institutes of Health · USInternational Tuberculosis Research Center · KR

Funding

International Research in Korea: Clinical Studies of Drug-Resistant TuberculosisZIAAI001067 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2017
$6.9M
Rapid Diagnosis of XDR TuberculosisR01AI080653 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ALLAND, DAVID · 2009 to 2013
$2.8M
NIAID NIH HHS AI080653NIAID NIH HHS R01 AI080653
6 · The paper itself

Abstract

Several molecular assays to detect resistance to Rifampin, the Fluoroquinolones, and Aminoglycosides in Mycobacterium tuberculosis (M. tuberculosis) have been recently described. A systematic approach for comparing these assays in the laboratory is needed in order to determine the relative advantage of each assay and to decide which ones should be advanced to evaluation. We performed an analytic comparison of a Sloppy Molecular Beacon (SMB) melting temperature (Tm) assay and a Dual labeled probe (DLP) Tm assay. Both assays targeted the M. tuberculosis rpoB, gyrA, rrs genes and the eis promoter region. The sensitivity and specificity to detect mutations, analytic limit of detection (LOD) and the detection of heteroresistance were tested using a panel of 56 clinical DNA samples from drug resistant M. tuberculosis strains. Both SMB and DLP assays detected 29/29 (100%) samples with rpoB RRDR mutations and 3/3 (100%) samples with eis promoter mutations correctly. The SMB assay detected all 17/17 gyrA mutants and 22/22 rrs mutants, while the DLP assay detected 16/17 (94%) gyrA mutants and 12/22 (55%) rrs mutants. Both assays showed comparable LODs for detecting rpoB and eis mutations; however, the SMB assay LODs were at least two logs better for detecting wild type and mutants in gyrA and rrs targets. The SMB assay was also moderately better at detecting heteroresistance. In summary, both assays appeared to be promising methods to detect drug resistance associated mutations in M. tuberculosis; however, the relative advantage of each assay varied under each test condition.

Indexed as

Molecular Diagnostic TechniquesMutationAminoglycosidesAntitubercular AgentsDNA, BacterialDNA Mutational AnalysisFluoroquinolonesHumansMicrobial Sensitivity TestsMycobacterium tuberculosisPolymerase Chain ReactionReproducibility of ResultsRifampinSensitivity and SpecificitySputumTuberculosis, Multidrug-ResistantAminoglycosidesAntitubercular AgentsDNA, BacterialFluoroquinolonesRifampin

Identifiers

PMID25938476
PMCPMC4418795
OpenAlexW258327222

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.